QIBA Executive Committee (EC) Conference-Call Meeting

Thursday, February 20, 2020 10:00 AM (CT) Draft Call Summary

Participants:

Daniel Sullivan, MD (QIBA Chair)
Alex Guimaraes, MD, PhD (QIBA Vice Chair)
Tim Hall, PhD (QIBA Vice Chair)
J. Brian Fowlkes, PhD
Rudresh Jarecha, MBBS
P. David Mozley, MD
Kevin O'Donnell, MASc
Nancy Obuchowski, PhD

RSNA Staff:

Angela Colmone, PhD Joe Koudelik Tori Peoples

Review of 10/10/19 and 1/23/20 call summaries

Call summaries were approved as distributed. Later edits should be submitted to RSNA staff at QIBA@rsna.org

Review of 2020 QIBA Annual Meeting Agenda

Dr. Sullivan noted that the Monday morning Coordinating Committee updates were to focus on major issues for the SC to be aware of or related to the general session topics.

The second half of the SC meeting will focus on the QIBA value proposition from a variety of perspectives. To obtain broad feedback, representatives from affiliated organizations have been invited to the SC meeting, e.g. MITA, MDIC, Pharma, CROs, cooperative groups, radiologists, physicists, engineers and government. Due to travel restrictions, SC reps from FDA and NIST will not be attending.

Dr. Sullivan has already reached out to CC leaders to reflect on Profile progress and consider what groundwork projects are needed and realistic sources of funding. This will be the focus of CC reports during the General Session. Profiles at Stage 2 or 3 are ideal examples for advancement and should be the focus of these CC discussions. Mr. O'Donnell reiterated the importance of reviewing the Profile Stages to realistically assess Profile progress.

The General Session will be further discussed on the March EC call. Dr. Sullivan plans to reach out to all moderators (and possibly panelists) to discuss the overall focus of the four plenary sessions: (1) Re-assessment of Profile Structure, (2) Information Dissemination, (3) Profile Conformance Testing and Accreditation, and (4) Moving Profiles to Stages 3 and 4.

Process Committee Update (O'Donnell)

Mr. O'Donnell noted that all Change Proposals voted upon by either the SC or EC will eventually be posted to the QIBA wiki for reference. Staff were requested to post an EC membership roster to the wiki.

Dr. Sullivan indicated that in 2010 a joint QIBA/RIC (RSNA Radiology Informatics Committee) had been created to address issues common to both groups. At the end of 2012, QIBA/RIC Committee responsibilities were assumed by the QIDW Oversight Committee. Due to a slow-down of committee action/involvement, the QIDW Oversight Committee was dissolved in July 2019, at which point QIDW oversight was shifted to the EC. To officially close this vestige of past leadership, a motion was made by Mr. O'Donnell, seconded by Dr. Mozley to dissolve the QIBA/RIC Committee. The motion was carried.

Mr. O'Donnell noted that he would flag the QIBA/RIC Committee as "dissolved" on the QIBA Wiki.

Potential New QI BCs

Dr. Fowlkes provided a brief overview of a new ultrasound biomarker of interest: Backscatter Quantitative Ultrasound Measurements based on tissue acoustic attenuation and scattering properties. There exists widespread interest in this biomarker, resulting in numerous discussions by QIBA and AIUM members, as well as equipment vendors. As done for the VBF BC, administrative support would be provided by AIUM staff.

Dr. Fowlkes speculated that it would be possible to create a Backscatter Profile within a 20-24 month timeframe, as research has already been done and there are abundant literature references.

There are possible synergies with other QIBA ultrasound BCs in efforts to develop a new phantom to measure several critical performance parameters. Construction of a new phantom and measuring on systems would require minimal groundwork. Dr. Mozley raised concern regarding the potential funding needed to develop a new phantom. Drs. Hall and Fowlkes reassured the EC that QIBA "resource consumption" would be minimal, as the BC would most likely rely on volunteer sites/manufacturers to help produce the phantoms, which would reduce funding needs to shipping costs. Since vendor assistance has been strong for both the SWS and VBF BCs, Dr. Fowlkes offered to reach out to phantom manufactures and ask for their endorsement of this BM proposal if needed.

At this time, it does not appear that Japan-QIBA is pursuing US Backscatter. Dr. Sullivan offered to follow up with Dr. Minoshima regarding a possible collaboration effort since Backscatter measurements are expected to become more mainstream in Japan.

A new Backscatter biomarker proposal has been drafted and will be reviewed and voted upon by the US CC members during their Q1 call on February 28th. If approved, the proposal will move up to the SC for review and approval on March 19th.

Sustainability Implementation Group (SIG) Update (Sullivan)

Dr. Sullivan noted that the RSNA Marketing Department created a new QIBA mark for the self-attestation arm of QIBA conformance. This mark is visually different from the Certified Conformance mark to distinguish the two levels of performance. Once the SIG has an opportunity to review the new mark, it will be circulated among EC members for reference.

Two strawman documents are being drafted regarding accreditation and pilot conformance procedures; these are on hold awaiting further SIG and QIBA leadership review.

Multiparametric Metrology Working Group (Obuchowski)

Dr. Obuchowski described the newly formed metrology subgroups that are focusing on four distinct use cases: (1) Phenotype Classification, (2) Multi-dimensional Descriptor, (3) Risk Prediction, and (4) Radiomics. Each subgroup is to draft a white paper on their subject with a fifth overview paper being drafted by Dr. Obuchowski. These papers are to help address overarching topics based on QIBA needs, e.g., how to test for Profile conformance in all four use cases. The subgroups are to host alternating bi-monthly calls over the next 10-12 months. A dedicated wiki page has been created for the Metrology Groups and their related efforts.

Next QIBA EC T-con Meeting:

Thursday, April 16, 2020 @ 10:00 AM (CT)